Assessment reveals enhanced cytotoxicity and immunologic memory in sdab-based CAR-T cells for multiple myeloma, suggesting potential for improved therapy.
Key Points
sdAb-based CAR-T cells exhibited enhanced cytotoxicity against BCMA-expressing cell lines in contrast to existing therapies.
Progression-free survival and increased IL-2 production were notable in sdAb-based CAR treatments.
Analysis involved surface plasmon resonance to evaluate affinity and interactions of therapeutic antibodies with cancer cells.
The findings suggest that next-generation CAR-T therapies may achieve improved long-term efficacy in relapsed multiple myeloma patients.
Cite This Study
Ibarra-Garcia et al. (2025) studied this question.